Journal of Medicinal Chemistry · 2005 · 43 citations · 19 references
Combinatorial ChemistryBioorganic ChemistryMolecular BiologyOrganic ChemistryMutant Hiv-1 StrainsChemistryParallel Solution-phasePharmaceutical ChemistrySubnanomolar Anti-hiv-1 ActivityMedicinal ChemistryHiv-1 StrainResistance Mutation (Virology)BiochemistryReverse TranscriptaseSynthesis MethodHivAntiviral CompoundMolecular ModelingNatural SciencesMedicineMicrowave-assisted SynthesisDrug Discovery
A simple and efficient methodology for the parallel solution-phase synthesis has been set up to obtain a series of thiouracils, in turn selectively S-benzylated under microwave irradiation to give new S-DABOs. Biological screening led to the identification of compounds with nanomolar activity toward both the highly purified recombinant human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) enzyme (wild-type and mutants) and wild-type (wt) and mutant HIV-1 strains. In particular, 20 was found to be the most potent S-DABO reported so far (ID50 = 26 nM toward the isolated wt enzyme) with subnanomolar activity toward both the wt and the pluriresistant virus (IRLL98) HIV-1 strain (EC50 < 0.14 nM and EC50 = 0.22 nM, respectively). Molecular modeling calculations were also performed to investigate the binding mode of such compounds onto the non-nucleoside reverse transcriptase inhibitor binding site and to rationalize the relationships between their chemical structure and activity values toward wt RT.
19
Inhibition of HIV-1 Replication by a Nonnucleoside Reverse Transcriptase Inhibitor
Vincent J. Merluzzi, Karl D. Hargrave, Mark E. Labadia et al. · Science · 1990 · 745 citations
Andrew L. Hopkins, Jingshan Ren, Robert Esnouf et al. · Journal of Medicinal Chemistry · 1996 · 339 citations · Full text
Stephen J. Smerdon, J. Jäger, J Wang et al. · Proceedings of the National Academy of Sciences · 1994 · 331 citations · Full text